Johnson Pharmacare Ltd
BSE:532154
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johnson Pharmacare Ltd
BSE:532154
|
IN |
|
Cranex Ltd
BSE:522001
|
IN |
|
Pitney Bowes Inc
NYSE:PBI
|
US |
Balance Sheet
Balance Sheet Decomposition
Johnson Pharmacare Ltd
Johnson Pharmacare Ltd
Balance Sheet
Johnson Pharmacare Ltd
| Mar-2006 | Mar-2007 | Mar-2008 | Mar-2009 | Mar-2010 | Mar-2011 | Mar-2012 | Mar-2013 | Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||
| Cash & Cash Equivalents |
8
|
6
|
4
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
2
|
0
|
0
|
0
|
0
|
|
| Cash |
8
|
6
|
4
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
2
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
198
|
138
|
0
|
78
|
78
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
32
|
39
|
12
|
78
|
177
|
0
|
162
|
155
|
119
|
36
|
139
|
32
|
40
|
49
|
46
|
54
|
11
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
36
|
7
|
11
|
9
|
0
|
162
|
122
|
82
|
4
|
126
|
0
|
0
|
9
|
9
|
17
|
11
|
0
|
0
|
0
|
|
| Other Receivables |
32
|
3
|
4
|
67
|
169
|
0
|
0
|
33
|
37
|
31
|
14
|
32
|
40
|
40
|
37
|
37
|
0
|
0
|
0
|
0
|
|
| Inventory |
43
|
73
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
14
|
|
| Total Current Assets |
82
|
118
|
16
|
81
|
180
|
3
|
164
|
356
|
260
|
38
|
221
|
114
|
43
|
52
|
49
|
56
|
11
|
0
|
0
|
14
|
|
| PP&E Net |
34
|
18
|
20
|
19
|
18
|
18
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
34
|
18
|
20
|
19
|
18
|
18
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
2
|
2
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
236
|
165
|
42
|
42
|
17
|
16
|
16
|
16
|
16
|
16
|
16
|
47
|
143
|
143
|
143
|
|
| Long-Term Investments |
19
|
0
|
86
|
71
|
103
|
404
|
245
|
194
|
299
|
540
|
353
|
459
|
540
|
531
|
523
|
523
|
542
|
456
|
456
|
423
|
|
| Other Long-Term Assets |
1
|
0
|
0
|
2
|
3
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
136
N/A
|
137
+0%
|
122
-11%
|
172
+42%
|
304
+77%
|
663
+118%
|
594
-10%
|
593
0%
|
601
+1%
|
595
-1%
|
590
-1%
|
590
0%
|
599
+2%
|
599
0%
|
588
-2%
|
595
+1%
|
600
+1%
|
598
0%
|
598
0%
|
579
-3%
|
|
| Liabilities | |||||||||||||||||||||
| Accounts Payable |
13
|
13
|
1
|
2
|
4
|
1
|
0
|
1
|
4
|
4
|
0
|
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
11
|
10
|
11
|
12
|
|
| Total Current Liabilities |
14
|
14
|
2
|
3
|
4
|
1
|
0
|
1
|
9
|
4
|
1
|
1
|
0
|
0
|
0
|
7
|
11
|
10
|
11
|
12
|
|
| Long-Term Debt |
22
|
22
|
20
|
69
|
76
|
73
|
6
|
6
|
6
|
6
|
6
|
6
|
17
|
17
|
6
|
7
|
6
|
19
|
20
|
6
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
36
N/A
|
37
+1%
|
22
-41%
|
72
+233%
|
80
+11%
|
75
-7%
|
6
-92%
|
7
+10%
|
16
+126%
|
11
-33%
|
7
-36%
|
7
+1%
|
17
+153%
|
17
N/A
|
6
-63%
|
13
+113%
|
17
+30%
|
29
+66%
|
31
+7%
|
18
-43%
|
|
| Equity | |||||||||||||||||||||
| Common Stock |
100
|
100
|
100
|
100
|
100
|
500
|
500
|
500
|
500
|
500
|
500
|
500
|
500
|
500
|
500
|
500
|
550
|
550
|
550
|
550
|
|
| Retained Earnings |
0
|
0
|
0
|
0
|
24
|
89
|
88
|
87
|
86
|
85
|
84
|
83
|
82
|
82
|
81
|
81
|
32
|
19
|
18
|
12
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
100
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
100
N/A
|
100
N/A
|
100
N/A
|
100
N/A
|
224
+124%
|
589
+163%
|
588
0%
|
587
0%
|
586
0%
|
585
0%
|
584
0%
|
583
0%
|
582
0%
|
582
0%
|
581
0%
|
581
N/A
|
582
+0%
|
569
-2%
|
568
0%
|
562
-1%
|
|
| Total Liabilities & Equity |
136
N/A
|
137
+0%
|
122
-11%
|
172
+42%
|
304
+77%
|
663
+118%
|
594
-10%
|
593
0%
|
601
+1%
|
595
-1%
|
590
-1%
|
590
0%
|
599
+2%
|
599
0%
|
588
-2%
|
595
+1%
|
600
+1%
|
598
0%
|
598
0%
|
579
-3%
|
|
| Shares Outstanding | |||||||||||||||||||||
| Common Shares Outstanding |
110
|
110
|
110
|
110
|
110
|
550
|
550
|
550
|
550
|
550
|
550
|
550
|
550
|
550
|
550
|
550
|
605
|
550
|
550
|
550
|
|